It’s only fair to share… Lanoracopan CAS 2797066-85-2 MFC27H32N2O4 MW448.6 g/mol 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid Benzoic acid, 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]- 4-{(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acidcomplement factor B inhibitor, MY 008211A, Factor B-IN-5, Y5UN7AE8SF Lanoracopan (also known by its developmental code MY008211A or Factor B-IN-5) is an investigational small-molecule drug that acts as a potent complement factor B (CFB) inhibitor. It is designed to …
Category «Uncategorized»
Lanisidenib
It’s only fair to share… lanisidenib, anax labs, isocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J Cas 2135537-20-9 MF C28H23ClF3N5O4S MW618.03 g/mol (3S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-1,1-dioxo-1,2-thiazolidine-3-carboxamide IUPAC Name: (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3, 3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo-1λ⁶,2-thiazolidine-3-carboxamide 3-Isothiazolidinecarboxamide, N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-, 1,1-dioxide, (3S)- (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo1λ6,2-thiazolidine-3-carboxamideisocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J Lanisidenib is a potent, selective isocitrate dehydrogenase (IDH) inhibitor that exhibits antineoplastic (anti-cancer) activity. It works by targeting abnormal IDH enzymes, which …
Itareparib
It’s only fair to share… Itareparib CAS 1606995-47-4 MF C20H26FN3O2 MW359.4 g/mol 2-(1-Cyclohexyl-4-piperidinyl)-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide 1H-ISOINDOLE-4-CARBOXAMIDE, 2-(1-CYCLOHEXYL-4-PIPERIDINYL)-6-FLUORO-2,3-DIHYDRO-3-OXO- 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole4-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, NMS-03305293, NMS-293, NMS 03305293, NMS 293, KFI1190L8L, NV 578, Itareparib is the inhibitor for PARP and exhibits antineoplastic activity. Itareparib (development code NMS-03305293 or NMS-293) is an experimental, next-generation PARP1-selective oral inhibitor being developed by the biopharmaceutical …
Irodanoprost
It’s only fair to share… Irodanoprost CAS 2055490-48-5 MF C34H44F2N2O13P2 MW788.7 g/mol 7-[(2R)-2-[(E,3R)-4,4-difluoro-3-[2-[4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl]acetyl]oxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid (2R)-2-[(1E,3R)-4,4-Difluoro-3-[[2-[4-[[(4-hydroxy-4,4-diphosphonobutyl)amino]carbonyl]phenyl]acetyl]oxy]-4-phenyl-1-buten-1-yl]-5-oxo-1-pyrrolidineheptanoic acid 7-[(2R)-2-{(1E,3R)-4,4-difluoro-3-[({4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl}acetyl)oxy]-4-phenylbut-1-en-1-yl}-5-oxopyrrolidin-1-yl]heptanoic acidprostaglandin receptor agonist, osteogenesis-related diseases, KP8BK46Z6R, MES 1022 Irodanoprost (also known as MES-1022) is a clinical-stage, bone- and pathology-targeted small molecule prodrug that acts as a potent and selective agonist for the prostaglandin E2 receptor subtype 4 (EP4). Developed …
Inidascamine
It’s only fair to share… Inidascamine CAS 903884-71-9 MF C12H17N3O2 MW235.28 g/mol (-)-(2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one (2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-oneschizophrenia, 3LW01V88B7, RL 007 Inidascamine (developmental code name RL-007 or FSV7-007) is an experimental, orally administered drug primarily studied for treating Cognitive Impairment Associated with Schizophrenia (CIAS). Developed jointly by Recognify Life Sciences and atai Life Sciences, the molecule targets the underlying …
Imofinostat
It’s only fair to share… Imofinostat CAS 1338320-94-7 MF C17H16N2O4S MW 344.4 g/mol (2E)-3-[1-(benzenesulfonyl)-2,3-dihydro-1H-indol-5-yl]-N-hydroxyprop2-enamidehistone deacetylase inhibitor, antineoplastic, ABT-301, MPT0E028, ABT 301, MPT0E 028, T65L58FI65 Imofinostat (also known as ABT-301 or MPT0E028) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor primarily being developed as an innovative precision oncology treatment. Developed by companies like AnBogen Therapeutics and …
Ifupinostat
It’s only fair to share… Ifupinostat CAS 1235449-52-1 MF C23H25N9O3S MW507.6 g/mol N-hydroxy-2-[methyl-[[2-[6-(methylamino)-3-pyridinyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide 5-Pyrimidinecarboxamide, N-hydroxy-2-(methyl((2-(6-(methylamino)-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)amino)- DQ7TD3X4ZJ, BEBT908 FREE BASE, Ifupinostat (brand name Betlin; formerly known as BEBT-908) is a first-in-class, dual-action cancer medication used to treat specific types of blood cancer. It is developed by the biopharmaceutical company BeBetter Med. Approved Clinical Use The drug is …
Gozanertinib
It’s only fair to share… Gozanertinib CAS 1226549-49-0 MF C32H31N5O3 MW533.6 g/mol (E)-4-(dimethylamino)-N-[3-[4-[[(1S)-2-hydroxy-1-phenylethyl]amino]-6-phenylfuro[2,3-d]pyrimidin-5-yl]phenyl]but-2-enamide (2E)-4-(dimethylamino)-N-[3-(4-{[(1S)-2-hydroxy-1-phenylethyl]amino}-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl]but-2-enamideepidermal growth factor receptor tyrosine kinase inhibitor, antineoplastic, DBPR 112, ABT 101, 6G0COS33K4 Gozanertinib (also known as DBPR112 or ABT-101) is an orally bioavailable, advanced small-molecule dual kinase inhibitor designed to treat advanced non-small cell lung cancer (NSCLC). It targets alterations in the …
Gintemetostat
It’s only fair to share… Gintemetostat (1S)-1-[(3R)-3-amino-4′-[(6-amino-9H-purin-9-yl)methyl]-6′-(2,5-difluoro-4-methoxyphenyl)-3,4,5,6-tetrahydro-2H-[1,3′-bipyridin]-3-yl]-2,2-difluoroethan1-olantineoplastic, KTX 1001, NSD2 inhibitor 161, A48CGJ5UQM CAS 2604513-16-6 MF C25H26F4N8O2 MW 546.5 g/mol (S)-1-((R)-3-Amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol Gintemetostat (also known as KTX-1001) is a first-in-class, orally administered small molecule being developed to treat relapsed and refractory multiple myeloma. It works as a selective inhibitor of NSD2 (also known as MMSET), targeting the …
Zidebactam
It’s only fair to share… Zidebactam FDA 2026, APPROVALS 2026 To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms CAS 1436861-97-0, UNII: YPM97423DB, Wockhardt Biopharm, WCK-5107, WCK5107 Molecular Formula, C13-H21-N5-O7-S Molecular Weight, 391.4029 Disclosed in PCT International Patent Application No. PCT/IB2012/054290D trans- sulphuric acid mono-[2-(N’-[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-l,6-diaza-bicyclo[3.2.1]oct-6-yl] ester (2S, 5R)-sulphuric acid mono-[2-(N’-[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-l,6-diaza-bicyclo[3.2.1]oct-6-yl] ester (1R,2S,5R)-l,6-Diazabicyclo …